Nanostructured Ketorolac-Tromethamine/MCF COMPOSITE. Drug release system

JORGELINA CUSSA; JULIANA M. JUAREZ; ANTONELA M. PRADOS; MARCOS B. GOMEZ COSTA; OSCAR ANUNZIATA

Cancún

Congreso; XXVII International Material Research Congress (IMRC 2018); 2018

IMRC

Nanoscale controlled drug delivery systems allowed for essential progress in pharmaceuticals, represent the change in medicine in the 21st century. Drug carriers were employed to improve therapeutic efficacy, inefficient amounts of drug and minimize adverse side effects. Controlled drug delivery systems maintain the concentration of drugs in the exact sites of the body, improving therapeutic efficacy and reducing toxicity. Mesostructured cellular foam (MCF) material is a new promising host for drug delivery systems due to high biocompatibility, in vivo biodegradability and low toxicity. Their properties include surface area and uniform large pore to load active drug, particle size distribution to control drug loading and release, noble biocompatibility and simple functionalized surface. In this work, MCF as a drug storage material was successfully synthesized and loaded with Ketorolac-Tromethamine drug, obtaining KETO/MCF composite. The material synthesis and process of inclusion of ketorolac-Tromethamine into MCF pores were successful as shown by XRD, FTIR, TGA, TEM and textural analyses. We obtained promising results for controlled drug release using the novel MCF material. The application of these materials in KETO release is innovative, achieving an initial high release rate and maintaining a constant rate at high times. This allows keeping drug concentration within the range of therapeutic efficacy, being highly applicable for the treatment of diseases that require a rapid response. The release behavior of the KETO material contained in MCF (KETO/MCF) was compared with that of KETO/SBA-15 system. Comparison showed encouraging results for the application of these materials as hosts/transporters in controlled drug release. The combination between the nanopore framework of MCF silica and drug improved properties in terms of resistance to dissolution, protection and prolonged release of the drug, enhancing the burst release process and providing a slower release of the residual bulkier drug. The KETO contained in MCF was weakly retained for the effective encapsulation and controlled release of drug, attaining the required therapeutic ability. The predominant release of KETO MCF was non-Fickian diffusion and the data obtained exhibited a better fit to Ritger-Peppas model.